Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 116 participants.

Also called NCT02966717

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 116 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02966717
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02966717. Randomized; no masking; primary purpose treatment. Start 2016-08 (registry gives no type); primary completion 2016-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)
Condition
Renal Insufficiency, Chronic
Condition
Nephrotic Syndrome
Intervention (Drug)
Rituximab
Intervention (Drug)
conventional therapy
Intervention (Drug)
Mesenchymal stem cells
Lead sponsor
Zhujiang Hospital (class: other)

Record details

Record id
cardio:ct-nct02966717
Content hash
63cf68fa60b0f37e56f6a894d5ed9ef6d4f330abbf1ef4d453eb13627ac485a1